Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
71
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Larimar Therapeutics Inc market cap is $336.92M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Larimar Therapeutics Inc 52 week high is $6.42 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Larimar Therapeutics Inc 52 week low is $1.92 as of November 20, 2026.
Larimar Therapeutics Inc stock price today is $3.14.
Larimar Therapeutics Inc stock price yesterday was $3.22.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Larimar Therapeutics Inc's P/E ratio is -1.62.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Larimar Therapeutics Inc P/B ratio is 2.6387.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Larimar Therapeutics Inc 50-day moving average is $2.87.